Results 21 to 30 of about 872 (156)

Effectiveness and Persistence in SB4‐ and Reference Etanercept–Treated Rheumatoid Arthritis Patients in Ordinary Clinical Practice in Norway

Arthritis Care &Research, Volume 75, Issue 9, Page 1986-1995, September 2023., 2023
Objective Biosimilars represent cost‐effective alternatives to reference biologic disease‐modifying antirheumatic drugs. Our objective was to compare drug effectiveness and drug persistence in the treatment of rheumatoid arthritis (RA), assessing the etanercept biosimilar SB4 in efficacy and safety compared with reference etanercept in a Phase III ...
Glenn Haugeberg, Gunnstein Bakland, Erik Rødevand, Inger Johanne Widding Hansen, Andreas Diamantopoulos, Are Hugo Pripp   +5 more
wiley   +1 more source

Strategies to enhance physical activity in people with Rheumatoid Arthritis: A Delphi survey

Musculoskeletal Care, Volume 21, Issue 3, Page 723-732, September 2023., 2023
Abstract Introduction Managing symptoms, resisting functional decline and maintaining health and independence are key motivators for people with Rheumatoid Arthritis (RA) who successfully engage with physical activity (PA). To inform PA support for people with RA the aim was to determine whether the broader RA population share similar beliefs and ...
Rachel Thomas, Alice Berry, Caroline Swales, Fiona Cramp   +3 more
wiley   +1 more source

Comparison of the inhibitory effect of tocilizumab and etanercept on the progression of joint erosion in rheumatoid arthritis treatment

Scientific Reports, 2022
We compared the efficacy of tocilizumab and etanercept in inhibiting radiographic progression of joint destruction in rheumatoid arthritis. Overall, 187 patients treated with etanercept or tocilizumab were selected.
Shinya Hayashi, Tsukasa Matsubara, Toshihisa Maeda, Koji Fukuda, Keiko Funahashi, Marowa Hashimoto, Ken Tsumiyama, Tomoyuki Kamenaga, Yoshinori Takashima, Tomoyuki Matsumoto, Shotaro Tachibana, Ryosuke Kuroda   +11 more
doaj   +1 more source

Scale Banking for Patient‐Reported Outcome Measures That Measure Functioning in Rheumatoid Arthritis: A Daily Activities Metric

Arthritis Care &Research, Volume 74, Issue 4, Page 579-587, April 2022., 2022
Objective Functioning is an important outcome for the management of rheumatoid arthritis (RA). Heterogeneity of respective patient‐reported outcome measures (PROMs) challenges direct comparisons between their results. This study aimed to standardize reporting of such PROMs measuring functioning in RA to facilitate comparability.
Birgit Prodinger, Michaela Coenen, Alison Hammond, Ayşe A. Küçükdeveci, Alan Tennant   +4 more
wiley   +1 more source

Oral and Intestinal Bacterial Substances Associated with Disease Activities in Patients with Rheumatoid Arthritis: A Cross‐Sectional Clinical Study

Journal of Immunology Research, Volume 2022, Issue 1, 2022., 2022
Intestinal bacterial compositions of rheumatoid arthritis (RA) patients have been reported to be different from those of healthy people. Dysbiosis, imbalance of the microbiota, is widely known to cause gut barrier damage, resulting in an influx of bacteria and their substances into host bloodstreams in animal studies.
Kaori Kitamura, Hiroshi Shionoya, Suguru Suzuki, Richio Fukai, Shinichi Uda, Chiyuki Abe, Hiromitsu Takemori, Keita Nishimura, Hisashi Baba, Kou Katayama, Kuniaki Terato, Takaki Waritani, Lihua Duan   +12 more
wiley   +1 more source

Effect of interleukin-17A inhibitor in Japanese patients with psoriatic arthritis compared with tumor necrosis factor-alpha inhibitor

Journal of Orthopaedic Surgery, 2021
Objectives: The patient of severe psoriatic arthritis (PsA) is mainly treated with oral methotrexate, ciclosporin, and anti-tumor necrosis factor-alpha inhibitors (TNFi). Recently, anti-interleukin-17A inhibitors (IL-17Ai) have been used in the treatment
Takuya Izumiyama, Yu Mori, Itsuki Oizumi, Soshi Hamada, Hiroaki Kurishima, Hitoshi Terui, Ryoko Omori-Shimada, Kenshi Yamasaki, Eiji Itoi   +8 more
doaj   +1 more source

Prevalence and Risk Factors of Substance Use Disorder in Rheumatoid Arthritis

ACR Open Rheumatology, Volume 3, Issue 12, Page 889-896, December 2021., 2021
Objective In this study, we aimed to determine the lifetime prevalence of substance use disorder (SUD) in a Canadian rheumatoid arthritis (RA) cohort and factors associated with SUD in RA. Methods Participants with RA (N = 154) were recruited via rheumatology clinics as part of a larger cohort study of psychiatric comorbidity in immune‐mediated ...
Kaarina Kowalec, Heather Carney, Mitulkumar Patel, Carol Hitchon, James M. Bolton, Scott B. Patten, Lesley A. Graff, Charles N. Bernstein, Christine Peschken, Ruth Ann Marrie, for the Canadian Institutes of Health Research Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease, Ruth Ann Marrie, James M. Bolton, Jitender Sareen, Scott B. Patten, Alexander Singer, Lisa M. Lix, Carol Hitchon, Renée El‐Gabalawy, Alan Katz, John D. Fisk, Charles N. Bernstein, Lesley A. Graff, Lindsay Berrigan, Christine Peschken, James Marriott   +25 more
wiley   +1 more source

Definition of activity cut-off point in patients with Behçet’s disease using the Arabic version of the Behcet’s Syndrome Activity Scale. [PDF]

Zagazig University Medical Journal, 2023
Background: Behçet’s disease (BD) activity assessment is a major concern since a treat-to-target approach may lead to a better prognosis. The first patient-reported assessment instrument, the Behçet's Syndrome Activity Score (BSAS), is useful for routine
dalia moatafa, Doaa Kamal, Amany Mohammed, SHYMAA SARHAN   +3 more
doaj   +1 more source

Common Functional Ability Score for Young People With Juvenile Idiopathic Arthritis

Arthritis Care &Research, Volume 73, Issue 7, Page 947-954, July 2021., 2021
Objective As young people enter adulthood, the interchangeable use of child and adult outcome measures may inaccurately capture changes over time. This study aimed to use item response theory (IRT) to model a continuous score for functional ability that can be used no matter which questionnaire is completed.
Stephanie J. W. Shoop‐Worrall, Martijn A. H. Oude Voshaar, Janet E. McDonagh, Mart A. F. J. Van de Laar, Nico Wulffraat, Wendy Thomson, Kimme L. Hyrich, Suzanne M. M. Verstappen   +7 more
wiley   +1 more source

Additional file 1 of A new instrument to measure high value, cost-conscious care attitudes among healthcare stakeholders: development of the MHAQ

, 2020
Additional file 1. The Maastricht HVCCC Attitude Questionnaire (MHAQ)
Frank Smeenk (8522547), Serge Mordang (8522544), Karen Könings (4349500), Aggie Paulus (3479483), Andrea Leep Hunderfund (4393726), Laurents Stassen (5328455)   +5 more
core   +1 more source